Department of Pharmaceuticals

Invitation of Tender for selection of reputed empanelled agencies with Government of India for conducting studies (Long Term and Short Term) and submission of report thereof.

*******

Frequently Asked Questions (FAQ):

Q. No. 1: We seek your comments w.r.t. applicability of the EMD clause for SMEs.

Ans: As per the pre-bid meeting discussion, the company Santek Consultant was requested to furnish the guidelines for exemption of the EMD clause for SMEs. However, the same is still awaited.

Q.No. 2: We understand that the Government has done away with most of the provisions of Attestation by Gazetted Officer, and made all documents acceptable if ‘Self-attested’, why is your department asking for documents to be certified by Chartered Accountant instead of them being ‘Self-attested’.

Ans: As the matter was discussed in the pre-bid meeting and it was informed that certification from Chartered Accountant is required for authentication of the documents and the same was agreed by the participating members in the meeting.

Q. No. 3: In your covering letter it is mentioned “reputed experienced empanelled agencies with Government of India”, but in your technical bid you have not asked for anything w.r.t. being empanelled. How will you assess this condition? Whether you mean to state that you will consider the list of empanelled organizations compiled by "Niti Aayog”?

Ans: ‘Reputed Experienced Empanelled Agencies with Government of India’ means any Agencies whether Government/Non-Government which are empanelled with the Ministries/Departments of Government of India and having experience in conducting/preparing study reports, market survey etc. Agencies empanelled with NITI Aayog will also be considered.
Q. No. 4: You have mentioned that the ‘terms and conditions of release of payment shall be as per the scheme guidelines’ - this is a vague statement, which needs to be clearly mentioned in detail in the tender document.

Ans: Scheme guidelines of the Pharmaceutical Promotion and Development Scheme (PPDS) are available on the website of the Department of Pharmaceuticals. In Scheme guidelines terms and conditions for release of payment are clearly mentioned. terms and conditions for release of payment are also mentioned in the Agreement (Annexure-II).

Q. No.5: Ideally, in such short time duration studies, a nodal officer is appointed from the Ministry to provide all secondary data and information, to facilitate the consultation, in a timely manner, whether this is stipulated for smoother conduction of the study or should be automatically assumed, that DOP will do it anyway?

Ans: As per clause 7.3. of the RFP, The Nodal Officer notified by the DoP will endeavor to provide a timely response to all queries. However, DoP makes no representation as to the completeness or accuracy of any response made in good faith.

Q. No. 6: Role of DOP in facilitating the smooth and timely conduction of the study is not mentioned any where?

Ans: The DoP has already specified the scope of work and timeline for completion of the studies which is self- explanatory

Q. No.7. What is mean by Mode and node in the Study to track medicines across the supply chain.

Ans: Reply Mode and node in the Study to track medicines across the supply chain relates to the nature of the distribution system which includes mode i.e., are the ways of the transport such as Air-Ways, Water-ways, Road Ways as well as volumes/variety of channels; and node implies the various levels of distribution of medicine such as Retailers, Distributors, Wholesaler, Company warehouse, Company supply chain.